Eli Lilly has released a new software that will permit self-pay out patients to purchase the weight-loss drug Zepbound for as small as $399 every month—fewer than 50 percent the record price of other incretin medicines useful for clients with obesity.Previous week, researchers documented that inside of a medical demo Zepbound and Mounjaro were ef